Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.

Trial Details

NCT ID
NCT06883526
Phase
PHASE1 / PHASE2
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • ZG005 for Injection
  • Gecacitinib Hydrochloride Tablets
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Fully understand this study and voluntarily sign the ICF;
  • Age ≥18 at ICF signing, regardless of gender;
  • Histologically confirmed relapsed or refractory lymphoma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →